Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722358 · ClinicalTrials.gov registry record · Phase 2
A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00722358 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 15 participants.
The verdict
NCT00722358, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the change in HCV RNA during dosing with BMS-650032 and during the follow-up period in subjects with chronic hepatitis C infection
Interventions
- DRUG Placebo
- DRUG BMS-650032
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00722358
The ClinicalTrials.gov registry entry for NCT00722358 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00722358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00722358 about?
NCT00722358 is a clinical study titled "A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects". The primary purpose of this study is to assess the change in HCV RNA during dosing with BMS-650032 and during the follow-up period in subjects with chronic hepatitis C infection
What is the current status of trial NCT00722358?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2008-12. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00722358?
The interventions under investigation include: Placebo (DRUG), BMS-650032 (DRUG).
Who is sponsoring clinical trial NCT00722358?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.